News & Events about Iteos Therapeutics Inc.
HC Wainwright reaffirmed their buy rating on shares of iTeos Therapeutics (NASDAQ:ITOS Get Rating) in a report published on Friday morning, Benzinga reports. The brokerage currently has a $54.00 price objective on the stock. Several other analysts have also recently issued reports on the stock. ...
Globe Newswire
11 months ago
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel ...
iTeos Therapeutics, Inc. (NASDAQ:ITOS Get Rating) saw a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 1,870,000 shares, a decrease of 7.4% from the October 31st total of 2,020,000 shares. Currently, 6.5% of the shares...
iTeos Therapeutics, Inc. (NASDAQ:ITOS Get Rating) Director David Hallal sold 1,171 shares of the companys stock in a transaction on Thursday, June 9th. The shares were sold at an average price of $19.51, for a total value of $22,846.21. The sale was disclosed in a legal filing with ...